Cancer chemotherapy and pharmacology
-
Cancer Chemother. Pharmacol. · Oct 2015
Multicenter StudyPhase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.
This phase I trial assessed afatinib, an irreversible ErbB family blocker, plus vinorelbine in Japanese patients with advanced solid tumors not amenable to standard treatment. ⋯ Afatinib 40 mg QD plus vinorelbine 25 mg/m(2) weekly was tolerated in Japanese patients when dose modifications for known AEs for either compound were allowed. Tumor shrinkage was also observed. This dose schedule was recommended for phase II/III trials in Japanese patients.